Seven PDUFA dates on FDA’s January agenda

The already strong growth of semaglutide may get another boost with Novo Nordisk expecting a decision this month on use of Ozempic to treat chronic kidney disease in Type II diabetes patients. 

Last year brought clinical readouts demonstrating the GLP-1 drug class may be useful for a variety of conditions beyond obesity and diabetes, including heart failure, MASH, sleep apnea and chronic kidney disease. Last month, sleep apnea data from competitor Eli Lilly and Co. (NYSE:LLY) led to FDA approval of Zepbound tirzepatide in the indication. Now, Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) hopes to add CKD to Ozempic’s label...